Further studies suggest that specific inhibition of BD1 can achieve similar anti-cancer efficacy as that of pan-BET inhibitors, whereas BD2 inhibitors show efficacy primarily in inflammatory and immune diseases. The gene discussed is DNER; the disease is cancer.